We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Patented Technology for Gentle Pumping of Biological Fluids

Lab equipment.
Credit: Biotech Fluidics.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Biotech Fluidics announce the foundation of Ventri Labs AB (VentriLabs) – a new subsidiary set-up to leverage the disruptive benefits of its patented gravity liquid pump technology for handling of sensitive media.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Use of conventional mechanical pumps is known to negatively affect sensitive biological materials limiting their use in bioprocessing, clinical and tissue engineering applications. Meticulously engineered to ensure delicate handling of sensitive media VentriLabs´ gravity-based pump technology is proven to reduce destructive mechanical and shearing effects by up to 95% while pumping blood, as compared to commonly used peristaltic pumps.



This innovative technology is also highly controllable, eliminating pulsation effects inherent in peristaltic and membrane pumps. In filtration applications this equates to improved efficiency and yields that translate into a more cost-efficient process for the user.

 

Dr Robin Öz, CEO of VentriLabs commented “Having committed multi-year funding from our parent company and a strong intellectual property portfolio – we are inviting collaborative partners and investors to accelerate the process, and further development of our groundbreaking liquid pump technology in lab, process and clinical applications.”